Targeting HER2 over-expression with trastuzumab in breast cancer has proven to be remarkably successful in clinical trials, which have demonstrated significant improvements in disease free survival and overall survival in breast cancer patients in the metastatic setting [3] and adjuvant setting [4, 5]. Here, ERBB2 is linked to breast carcinoma.